Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

Elihu H. Estey*, Peter F. Thall, Jorge E. Cortes, Francis J. Giles, Susan O'Brien, Sherry A. Pierce, Xuemei Wang, Hagop M. Kantarjian, Miloslav Beran

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

145 Scopus citations

Fingerprint

Dive into the research topics of 'Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases